Gene Therapy Vector for the Treatment of Glycogen Storage Disease Type Ia (GSD-Ia)


GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). Current therapy, which primarily consists of dietary modification, fails to prevent long-term complications in many patients, including growth failure, gout, pulmonary hypertension, renal dysfunction, osteoporosis, and hepatocellular adenomas (HCA). Gene therapy-based techniques, which directly address the underlying genetic deficiency driving the disorder, offer the prospect of long-term remission in patients with GSD-Ia.

Researchers at the NIH National Insitute for Childhood Health and Diseases have developed an adeno-associated viral (AAV) vector for the treatment of glycogen storage disease type Ia (GSD-Ia).This new AAV vector that expresses human G6Pase-alpha directed by the tissue-specific human G6PC promoter/enhancer incorporates two improvements: 1) it expresses a variant of G6Pase-alpha with enhanced enzymatic activity; 2) it is codon optimized to achieve higher enzyme expression levels and enhanced enzymatic activity.

In vivo data is available.



Potential Commercial Applications: Competitive Advantages:
  • Gene therapy vector for the treatment of GSD-Ia
 
  • Protein coding sequence modified for enhanced enzymatic activity.
  • Codon optimized for increased enzyme expression in target organs.


Development Stage:
Pre-clinical (in vivo)

Related Invention(s):
E-552-2013


Inventors:

Janice Chou (NICHD)  ➽ more inventions...


Intellectual Property:
US Provisional Application No. 62/096,400

Publications:
Lee YM et al.  [PMID 22422504]
Lee YM, et al.  [PMID 23856420]

Collaboration Opportunity:

Licensing only


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-039-2015
Updated: Mar 9, 2018